Lucid Diagnostics Inc. (LUCD)
Lucid Diagnostics Statistics
Share Statistics
Lucid Diagnostics has 105.38M shares outstanding. The number of shares has increased by 65.7% in one year.
| Shares Outstanding | 105.38M |
| Shares Change (YoY) | 65.7% |
| Shares Change (QoQ) | 46.36% |
| Owned by Institutions (%) | 6.57% |
| Shares Floating | 40.01M |
| Failed to Deliver (FTD) Shares | 13.21K |
| FTD / Avg. Volume | 1.23% |
Short Selling Information
The latest short interest is 1.6M, so 1.52% of the outstanding shares have been sold short.
| Short Interest | 1.6M |
| Short % of Shares Out | 1.52% |
| Short % of Float | 2.29% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.91 and the forward PE ratio is -3.8. Lucid Diagnostics's PEG ratio is 0.02.
| PE Ratio | -0.91 |
| Forward PE | -3.8 |
| PS Ratio | 0.01 |
| Forward PS | 2.4 |
| PB Ratio | 0.01 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0.02 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Lucid Diagnostics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.07, with a Debt / Equity ratio of 3.94.
| Current Ratio | 1.07 |
| Quick Ratio | 1.07 |
| Debt / Equity | 3.94 |
| Debt / EBITDA | -0.46 |
| Debt / FCF | -0.48 |
| Interest Coverage | -1771230.77 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $60.36M |
| Profits Per Employee | $-632.35K |
| Employee Count | 72 |
| Asset Turnover | 0.14 |
| Inventory Turnover | 20.82K |
Taxes
| Income Tax | 7.5B |
| Effective Tax Rate | -16.46% |
Stock Price Statistics
The stock price has increased by 35.79% in the last 52 weeks. The beta is 1.26, so Lucid Diagnostics's price volatility has been higher than the market average.
| Beta | 1.26 |
| 52-Week Price Change | 35.79% |
| 50-Day Moving Average | 1.39 |
| 200-Day Moving Average | 1.01 |
| Relative Strength Index (RSI) | 47.76 |
| Average Volume (20 Days) | 1.07M |
Income Statement
In the last 12 months, Lucid Diagnostics had revenue of 4.35B and earned -45.53M in profits. Earnings per share was -0.75.
| Revenue | 4.35B |
| Gross Profit | -2.75B |
| Operating Income | -46.05B |
| Net Income | -45.53M |
| EBITDA | -46.05B |
| EBIT | -45.55B |
| Earnings Per Share (EPS) | -0.75 |
Balance Sheet
The company has 22.36B in cash and 21.25B in debt, giving a net cash position of 1.1B.
| Cash & Cash Equivalents | 22.36B |
| Total Debt | 21.25B |
| Net Cash | 1.1B |
| Retained Earnings | -203.77B |
| Total Assets | 30.71M |
| Working Capital | 1.62M |
Cash Flow
In the last 12 months, operating cash flow was -44.14B and capital expenditures 0, giving a free cash flow of -44.14B.
| Operating Cash Flow | -44.14B |
| Capital Expenditures | 0 |
| Free Cash Flow | -44.14B |
| FCF Per Share | -873.79 |
Margins
Gross margin is -63.35%, with operating and profit margins of -1059.64% and -1.05%.
| Gross Margin | -63.35% |
| Operating Margin | -1059.64% |
| Pretax Margin | -1047.61% |
| Profit Margin | -1.05% |
| EBITDA Margin | -1059.64% |
| EBIT Margin | -1059.64% |
| FCF Margin | -1015.65% |
Dividends & Yields
LUCD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for LUCD is $3, which is 132.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $3 |
| Price Target Difference | 132.6% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -10.79 |
| Piotroski F-Score | 4 |